Immunomodulation and reversal of airway remodeling in asthma

Current Opinion in Allergy and Clinical Immunology

Volumn 4, Issue 6, 2004, Pages 529-532

  Broide, David ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CPG DNA; CYTOKINE; DNA; INTERLEUKIN 10; INTERLEUKIN 5; STEROID; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AIRWAY; ALLERGIC RHINITIS; ASTHMA; BRONCHUS REACTIVITY; CHRONIC DISEASE; CLINICAL TRIAL; CPG ISLAND; DISEASE EXACERBATION; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; LONG TERM CARE; META ANALYSIS; MORBIDITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TH2 CELL; UNITED STATES;

AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ANIMALS; ANTIBODIES; ASTHMA; CPG ISLANDS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-5; RESPIRATORY SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 9644274023     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200412000-00009     Document Type: Editorial

References (28)

1. von Mutius E. Influences in allergy: epidemiology and the environment. J Allergy Clin Immunol 2004; 113:373-379.
2. Apter AJ, Szefler SJ. Advances in adult and pediatric asthma. J Allergy Clin Immunol 2004; 113:407-414.
3. McFadden ER. Acute severe asthma. Am J Respir Crit Care Med 2003; 168:740-759.
4. Creticos PS. The consideration of immunotherapy in the treatment of allergic asthma. J Allergy Clin Immunol 2000; 105:3559-3574.
5. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-475.
6. Dinakar C, Portnoy JM. Allergen immunotherapy in the prevention of asthma. Curr Opin Allergy Clin Immunol 2004; 4:131-136.
7. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2004; 113:635-642.
8. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-256.
9. Bousquet J. Pro: Immunotherapy is clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med 2001; 164:2139-2140.
10. Adkinson NF Jr. Con: Immunotherapy is not clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med 2001; 164:2140-2141.
11. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003; 4:CD001186.
12. Cho JY, Miller M, Baek KJ, et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 2004; 113:551-560.
13. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-1036.
14. Cho JY, Miller M, Baek KJ, et al. Immunostimulatory DNA inhibits transforming growth factor-beta expression and airway remodeling. Am J Respir Cell Mol Biol 2004; 30:651-661.
15. Ikeda RK, Miller M, Nayar J, et al. Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. J Immunol 2003; 171:4860-4867.
16. Cho JY, Miller M, Baek KJ, et al. Immunostimulatory DNA reverses established allergen induced airway remodeling. J Immunol (in press).
17. Fanucchi MV, Schelegle ES, Baker GL, et al. Immunostimulatory oligonucleotides attenuate airways remodelling in allergic monkeys. Am J Respir Crit Care Med (in press).
18. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342:1350-1358.
19. Vignola AM, Chanez P, Chiappara G, et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 1997; 156:591-599.
20. Redington AE, Madden J, Frew AJ, et al. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 1997; 156:642-647.
21. Elias JA, Lee CG, Zheng T, et al. New insights into the pathogenesis of asthma. J Clin Invest 2003; 111:291-297.
22. Chakir J, Shannon J, Molet S, et al. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol 2003; 111:1293-1298.
23. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96:319-328.
24. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-745.
25. Broide D, Schwarze J, Tighe H, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998; 161:7054-7062.
26. Kline JN, Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160:2555-2559.
27. Cho JY, Miller M, Baek KJ, et al. ISS and RSV immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion. J Allergy Clin Immunol 2001; 108:697-702.
28. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159:1043-1051.